• Article Graphic
  • Article Graphic
  • Article Graphic
  • Article Graphic

Who We Are

Leidos Logo

The Frederick National Laboratory for Cancer Research (FNLCR) is a Federally Funded Research and Development Center (FFRDC) operated by Leidos Biomedical Research, Inc., (formerly SAIC-Frederick, Inc.) for the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH).

The FNLCR provides quick response capabilities and meets special long-term research and development needs for NCI that cannot be met as effectively by existing in-house or contractor resources. More about Leidos Biomedical Research

Scientific Impact

With our partners, we are developing faster and less expensive ways of turning laboratory discoveries into new diagnostic tests and treatments for cancer and AIDS.

Type of work ranges from basic research, translational research, technology development and research support, and clincial/pre-clinical development. Read about some of our success stories below.

View our Scientific Impact gallery.

Business Opps

Thank you for your interest in doing business with the Frederick National Laboratory for Cancer Research (FNLCR).

FNLCR is a Federally Funded Research and Development Center (FFRDC) operated by Leidos Biomedical Research under prime contract with the National Cancer Institute.

Extensive business opportunities exist for providing an array of vital goods and services in support of the operational, technical and research efforts required at the FFRDC.View our contracting opportunities.

Outreach

The Frederick National Laboratory for Cancer Research and its prime contractor, Leidos Biomedical Research, Inc., are actively involved in nurturing the community in which their employees live and work. The campus supports a wide cross section of nonprofit organizations and charities. Frederick National Lab sponsors a series of educational programs from grade school through graduate school.

Read more about how we support our mission in the areas of business, health and more.

National Mission

The Frederick National Laboratory for Cancer Research is undertaking a coordinated research and development program to further scientific understanding of cancers driven by mutations in RAS family of genes. These genes, when mutated, give rise to 30 percent of all cancers and 95 percent of pancreatic cancers. RAS-driven cancers are virtually impossible to treat successfully and, in some cases, are actually aggravated by current targeted therapies.

The Frederick National Lab is part of an integrated program that will enlist collaborators from all sectors of the research community nationwide with the goal of developing effective new therapies to treat RAS-driven cancers. It's a high-risk undertaking that could result in big dividends for human health if successful.

Read more about the RAS Program.

News & Events

Current news, announcements, and events.